Mara Goldstein
Stock Analyst at Clear Street
(0.16)
# 4,703
Out of 5,088 analysts
1004
Total ratings
34.5%
Success rate
-4.7%
Average return
Main Sectors:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BEAM Beam Therapeutics | Reiterated: Buy | $37 | $28.84 | +28.29% | 1 | Sep 9, 2026 | |
| MOLN Molecular Partners AG | Reiterated: Buy | $8 | $3.53 | +126.63% | 1 | Sep 4, 2026 | |
| SMMT Summit Therapeutics | Reiterated: Buy | $31 | $16.20 | +91.36% | 2 | Sep 3, 2026 | |
| RGNX REGENXBIO | Reiterated: Buy | $45 → $32 | $7.41 | +331.85% | 4 | Aug 25, 2026 | |
| WVE Wave Life Sciences | Reiterated: Buy | $26 | $3.63 | +616.25% | 1 | Aug 3, 2026 | |
| KURA Kura Oncology | Reiterated: Buy | $32 → $30 | $10.56 | n/a | 5 | Aug 18, 2025 | |
| INCY Incyte | Reiterated: Hold | $77 → $74 | $116.80 | n/a | 73 | Aug 4, 2025 | |
| IOVA Iovance Biotherapeutics | Reiterated: Buy | $30 | $9.56 | n/a | 50 | Feb 8, 2024 | |
| MRK Merck & Co. | Reiterated: Buy | $138 | $146.33 | n/a | 121 | Feb 5, 2024 | |
| ADAPY Adaptimmune Therapeutics plc | Reiterated: Buy | $9 | $0.0261 | n/a | 47 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $51 → $42 | $18.61 | n/a | 79 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $14.15 | n/a | 3 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $3.31 | n/a | 31 | Jan 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $1.58 | n/a | 54 | Jan 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $59 → $50 | $29.21 | n/a | 55 | Jan 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $175 → $7 | $0.0002 | n/a | 23 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $14.98 | n/a | 12 | Jan 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $36 | $9.66 | n/a | 44 | Jan 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $2.17 | n/a | 49 | Jan 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2 | $2.29 | n/a | 51 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $0.9801 | n/a | 33 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $4.02 | n/a | 8 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $3.5 | $10.23 | n/a | 49 | Dec 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $6 → $5 | $39.18 | n/a | 25 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $28.82 | n/a | 26 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2 | $0.7422 | n/a | 7 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.11396 | n/a | 2 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $150.30 | n/a | 5 | Oct 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $31.45 | n/a | 2 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $8.37 | n/a | 1 | Jun 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 → $14 | $63.31 | n/a | 17 | Sep 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $6 | $1.23 | n/a | 27 | Jun 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 → $25 | $0.8798 | n/a | 14 | May 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.000001 | n/a | 3 | Apr 18, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $135 → $45 | $29.89 | n/a | 24 | Apr 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $3.10 | n/a | 18 | Mar 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12.11 | $0.85 | n/a | 1 | Dec 29, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $13 | $143.45 | n/a | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $277 | $249.65 | n/a | 1 | Apr 28, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $7 | $12.15 | n/a | 8 | Apr 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $0.4935 | n/a | 1 | Apr 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2 → $14 | $1.05 | n/a | 4 | Apr 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $0.833 | n/a | 2 | Oct 7, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.0006 | n/a | 9 | Apr 7, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $2 | $10.16 | n/a | 8 | Dec 8, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $4 → $2 | $0.0001 | n/a | 2 | Jan 24, 2014 |
Beam Therapeutics
Sep 9, 2026
Reiterated: Buy
Price Target: $37
Current: $28.84
Upside: +28.29%
Molecular Partners AG
Sep 4, 2026
Reiterated: Buy
Price Target: $8
Current: $3.53
Upside: +126.63%
Summit Therapeutics
Sep 3, 2026
Reiterated: Buy
Price Target: $31
Current: $16.20
Upside: +91.36%
REGENXBIO
Aug 25, 2026
Reiterated: Buy
Price Target: $45 → $32
Current: $7.41
Upside: +331.85%
Wave Life Sciences
Aug 3, 2026
Reiterated: Buy
Price Target: $26
Current: $3.63
Upside: +616.25%
Kura Oncology
Aug 18, 2025
Reiterated: Buy
Price Target: $32 → $30
Current: $10.56
Upside: n/a
Incyte
Aug 4, 2025
Reiterated: Hold
Price Target: $77 → $74
Current: $116.80
Upside: n/a
Iovance Biotherapeutics
Feb 8, 2024
Reiterated: Buy
Price Target: $30
Current: $9.56
Upside: n/a
Merck & Co.
Feb 5, 2024
Reiterated: Buy
Price Target: $138
Current: $146.33
Upside: n/a
Adaptimmune Therapeutics plc
Jan 31, 2024
Reiterated: Buy
Price Target: $9
Current: $0.0261
Upside: n/a
Jan 29, 2024
Reiterated: Buy
Price Target: $51 → $42
Current: $18.61
Upside: n/a
Jan 24, 2024
Reiterated: Buy
Price Target: $45
Current: $14.15
Upside: n/a
Jan 23, 2024
Reiterated: Buy
Price Target: $12
Current: $3.31
Upside: n/a
Jan 22, 2024
Reiterated: Buy
Price Target: $12
Current: $1.58
Upside: n/a
Jan 21, 2024
Rated: Buy
Price Target: $59 → $50
Current: $29.21
Upside: n/a
Jan 16, 2024
Reiterated: Buy
Price Target: $175 → $7
Current: $0.0002
Upside: n/a
Jan 15, 2024
Reiterated: Buy
Price Target: $7
Current: $14.98
Upside: n/a
Jan 15, 2024
Reiterated: Buy
Price Target: $36
Current: $9.66
Upside: n/a
Jan 12, 2024
Reiterated: Buy
Price Target: $8
Current: $2.17
Upside: n/a
Jan 5, 2024
Reiterated: Hold
Price Target: $2
Current: $2.29
Upside: n/a
Jan 4, 2024
Reiterated: Buy
Price Target: $8
Current: $0.9801
Upside: n/a
Dec 12, 2023
Reiterated: Buy
Price Target: $20
Current: $4.02
Upside: n/a
Dec 10, 2023
Rated: Hold
Price Target: $3.5
Current: $10.23
Upside: n/a
Nov 8, 2023
Rated: Hold
Price Target: $6 → $5
Current: $39.18
Upside: n/a
Aug 4, 2023
Rated: Hold
Price Target: n/a
Current: $28.82
Upside: n/a
May 16, 2022
Reiterated: Hold
Price Target: $2
Current: $0.7422
Upside: n/a
Feb 18, 2022
Rated: Hold
Price Target: n/a
Current: $0.11396
Upside: n/a
Oct 1, 2021
Reiterated: Buy
Price Target: n/a
Current: $150.30
Upside: n/a
Jun 8, 2021
Reiterated: Buy
Price Target: n/a
Current: $31.45
Upside: n/a
Jun 22, 2020
Reiterated: Buy
Price Target: $24
Current: $8.37
Upside: n/a
Sep 20, 2018
Initiated Coverage: Buy
Price Target: $10 → $14
Current: $63.31
Upside: n/a
Jun 13, 2018
Reiterated: Hold
Price Target: $6
Current: $1.23
Upside: n/a
May 1, 2018
Reiterated: Buy
Price Target: $18 → $25
Current: $0.8798
Upside: n/a
Apr 18, 2018
Reiterated: Buy
Price Target: $5
Current: $0.000001
Upside: n/a
Apr 16, 2018
Downgraded: Hold
Price Target: $135 → $45
Current: $29.89
Upside: n/a
Mar 19, 2018
Reiterated: Buy
Price Target: $12
Current: $3.10
Upside: n/a
Dec 29, 2017
Reiterated: Buy
Price Target: $12.11
Current: $0.85
Upside: n/a
Dec 1, 2017
Rated: Buy
Price Target: $13
Current: $143.45
Upside: n/a
Apr 28, 2017
Reiterated: Hold
Price Target: $277
Current: $249.65
Upside: n/a
Apr 13, 2017
Reiterated: Hold
Price Target: $7
Current: $12.15
Upside: n/a
Apr 13, 2017
Reiterated: Buy
Price Target: $15
Current: $0.4935
Upside: n/a
Apr 13, 2017
Reiterated: Hold
Price Target: $2 → $14
Current: $1.05
Upside: n/a
Oct 7, 2016
Reiterated: Buy
Price Target: $7
Current: $0.833
Upside: n/a
Apr 7, 2016
Reiterated: Buy
Price Target: n/a
Current: $0.0006
Upside: n/a
Dec 8, 2015
Upgraded: Hold
Price Target: $2
Current: $10.16
Upside: n/a
Jan 24, 2014
Downgraded: Hold
Price Target: $4 → $2
Current: $0.0001
Upside: n/a